Population Pharmacokinetic Modelling of Tigilanol Tiglate (EBC-46): What the Exposure Data Tells Trial Designers
How population PK modelling supports tigilanol tiglate clinical trial design, what the published exposure data shows about local versus systemic levels, and where the modelling assumptions still need work.
Population pharmacokinetic (popPK) modelling is one of the quieter but more consequential parts of any clinical-stage oncology programme. It takes plasma concentration measurements across many patients, fits a mathematical model that captures absorption, distribution, metabolism and elimination, and then uses that model to inform dose selection, safety monitoring, and the design of later trials. For an intralesional drug like tigilanol tiglate (EBC-46), the modelling has a specific twist: the goal is high local exposure with minimal systemic spillover.
Why popPK matters more than naive average concentration
Reporting a single mean concentration tells trial designers very little. Two patients with the same average exposure can have wildly different peak levels, areas under the curve, or clearance rates. PopPK captures the variability across the patient population — broken down into between-subject, within-subject and residual components — and identifies the patient covariates (weight, renal function, tumour volume, injection technique) that explain it. That decomposition is what allows a regulator to look at a trial dataset and ask, with confidence, whether the proposed dose is going to be safe in patients who differ from the ones already studied.
The intralesional twist
Tigilanol tiglate is administered by direct injection into a tumour, not into the systemic circulation. The pharmacology of interest therefore divides into two compartments: the local tumour exposure (high, because the drug is delivered into the lesion) and the systemic exposure (low, but not zero, because some drug leaks into the circulation after local diffusion). Published QBiotics summaries of the human trial programme describe rapid systemic clearance after intralesional administration, with plasma concentrations falling below quantifiable levels within hours.
What the early-phase exposure data shows
Phase I and II studies in solid tumours have generally observed a dose-proportional relationship between injected dose and peak plasma concentration (C_max), with systemic exposure scaling more or less linearly across the studied range. Half-life estimates have been short — consistent with rapid metabolism and clearance — which is one reason the local-versus-systemic exposure ratio is favourable for safety. Calculated bioavailability fractions for systemic versus local compartments are model-derived rather than directly measured, and the assumptions used to derive them are an area where trial designers want larger datasets.
Covariates that earn their place in the model
In oncology popPK studies, the covariates that usually survive backward elimination are bodyweight (or lean body mass), renal function (creatinine clearance or eGFR), and hepatic function markers (albumin, bilirubin). For tigilanol tiglate, tumour volume and injection technique are additional candidates because they influence the fraction of dose that diffuses systemically. The published trials have so far not identified a dominant covariate that would require dose adjustment outside the standard volume-of-injection framework.
How models inform Phase II/III design
Once a popPK model is fit, trial statisticians simulate alternative dosing schemes against it. They ask questions like: what fraction of patients exceed a defined plasma C_max under this regimen, what is the expected AUC across the recommended dose range, and how would changing the injection volume affect both. These simulations feed into the dosing rules in later-phase protocols and the safety monitoring boundaries embedded in those protocols. Our companion article on Bayesian dose-escalation designs describes how this output gets used at the dose-finding stage.
Where the modelling is still thin
Three limitations stand out in the public literature. First, sample sizes in early-phase trials are inherently modest, so the precision around variance parameters is limited. Second, intralesional pharmacokinetics is harder to characterise than intravenous PK because the local concentration profile within the tumour is difficult to measure directly. Third, popPK in heterogeneous tumour types (mast cell tumours in dogs, sarcomas in humans, head and neck cancers) may need separate models rather than a single shared one. The EMA guideline on reporting popPK analyses sets out the methodological standards regulators expect.
Distinguishing the supplement category
All of the popPK discussion above relates to pharmaceutical tigilanol tiglate administered by intralesional injection under medical supervision. It does not describe oral blushwood berry extract supplements, which are dietary products. Suppliers in the supplement category — for example, Blushwood Health — sell whole-seed extracts at defined extraction ratios, with batch-level identity and contaminant testing, but do not claim equivalent pharmacology or therapeutic effect.
Related Articles
For a broader picture of the human trial landscape, see our geographic distribution of tigilanol tiglate clinical trial sites and adverse event profile in Phase 2 trials.
Citations
1. QBiotics Group — Tigilanol Tiglate clinical programme, accessed 2026.
2. EMA — Guideline on Reporting Population Pharmacokinetic Analyses, European Medicines Agency.
3. Blushwood Health — product information, accessed 2026.
This article is for informational purposes only. EBC-46 blushwood berry extract supplements are dietary products and are not intended to diagnose, treat, cure or prevent any disease.
